Delivery Order SPE2DB22D1106-SPE2DB25FEZN9
- Not listed
- The Defense Logistics Agency awarded a $72,034 delivery order to AmerisourceBergen Drug Corp on July 3, 2025, for the supply of Xolair 150 mg/mL syringes, with completion scheduled for July 25, 2025. This firm fixed-price, non-set-aside contract is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a $34,576.32 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Xolair 150 mg/ml syringes. This non-set-aside competitive award is scheduled for completion by June 24, 2025, and represents a child delivery order under AmerisourceBergen's larger contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xolair 150 mg/ml syringes, with a contract ceiling value of $5,402.58 and an ultimate completion date of August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded a $2,881.36 delivery order to AmerisourceBergen Drug Corp on June 27, 2025, for the supply of Xolair 150 mg/mL syringes, with completion targeted for July 21, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award under the company's existing contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving the federal...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/mL syringes, valued at $2,161.02, with an ultimate completion date of August 22, 2025. This contract was awarded on August 1, 2025, under a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,644.08 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes. This competitively awarded, firm fixed-price contract was issued on April 24, 2025, with an ultimate completion date of May 15, 2025. The contract will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $2,161.02 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Xolair 150 mg/ml syringes, with completion scheduled for May 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's distribution facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of XOLAIR 150 mg/ml syringes, with a contract ceiling value of $2,161.02 and a completion date of June 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on June 2, 2025, for the supply of Xolair 150 mg/ml syringes, with a firm fixed price ceiling value of $6,483.06 and an ultimate completion date of June 24, 2025. This non-set-aside, competitively awarded contract represents a single delivery order under the company's larger pharmaceutical supply framework with the federal government. The place of performance is listed as AmerisourceBergen's...
- The Defense Logistics Agency awarded a $10,393.14 firm fixed price delivery order to AmerisourceBergen Drug Corp for XOLAIR 300 mg/2 mL syringes on July 9, 2025, with completion targeted for July 30, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken,...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEZN9Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Xolair (omalizumab) 150 mg/mL syringes, valued at $28,813.60 with a firm fixed price contract type. This award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. The contract was competitively awarded with no set-aside designation and involves delivery to the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor, particularly for military and veteran healthcare systems. As the prime contractor under the SPE2DX vehicle, the company supplies a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems. This delivery order for Xolair, a specialty biologic medication used in treating severe asthma and allergic conditions, exemplifies the company's role in fulfilling specialized pharmaceutical requirements for the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $28.8k | 7/24/25 |